---
schema_version: "secwatch.filing_event.v1"
accession: "0001386570-25-000011"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:02:11.936867+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Niagen Bioscience Q2 net sales up 37% to $31.1M; raises FY2025 guidance to 22%-27% growth

## Summary
- Net sales $31.1M (+37% YoY); net income $3.6M ($0.05 EPS) vs breakeven in Q2 2024.
- Gross margin improved 480 bps to 65.0%; adjusted EBITDA $5.0M, up 221%.
- Raises FY2025 revenue growth outlook to 22%-27% (previously 20%-25%).
- Secured exclusive worldwide license for Niagen in Parkinson's therapy; NOPARK Phase III trial dosing completed, data expected 2026.
- Niagen Plus available in 800+ U.S. wellness clinics (up from 475 in Dec 2024); cash $60.5M.

## SEC filing metadata
- accession: 0001386570-25-000011
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000138657025000011/0001386570-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000138657025000011/cdxc-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001386570-25-000011
- JSON: https://secwatch.observer/filing/0001386570-25-000011.json
- Plain text: https://secwatch.observer/filing/0001386570-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.